Pharmacy benefit managers have opened a dedicated audit line for brand GLP-1 claims, running semaglutide and tirzepatide dispensing through the same recoupment and network-termination machinery built for older high-dollar drug classes. The reviews center on whether the diagnosis on file supports the specific product billed, whether the prior authorization on record matches the plan's current criteria, and whether the dispensing pattern lines up with the drug's approved dosing schedule. A pharmacy that filled the prescription exactly as written can still face a six-figure PBM audit finding if the underlying medical record does not document the coverage criteria the PBM applies after the fact.
Coverage Criteria and the Diagnosis Mismatch
Most GLP-1 receptor agonists carry more than one FDA-approved indication, and PBMs administer separate coverage criteria for each. A brand product approved for type 2 diabetes management is typically covered under a diabetes-focused prior authorization; the same class of molecule marketed under a different brand for chronic weight management is covered, when it is covered at all, under stricter criteria tied to body mass index and documented comorbidities. Auditors compare the diagnosis code on the pharmacy claim against the product's approved labeling and the plan's coverage policy for that specific brand. A weight-management-indicated product billed against a diabetes diagnosis alone, or a diabetes-indicated product dispensed to a patient whose chart shows no diabetes history, is one of the most common triggers for a full-scope GLP-1 audit.
Prior Authorization Records PBMs Expect
A pharmacy's own dispensing record rarely satisfies a PBM auditor on its own. Auditors request the prior authorization approval itself, the prescriber's supporting chart notes, and, for weight-management coverage, documentation of the patient's body mass index and any comorbid conditions the plan's criteria name. MedImpact audit findings and Navitus audits in other high-dollar drug classes show the same pattern: both PBMs have built GLP-1-specific checklists into their standard audit workflow, and a pharmacy that keeps only the authorization number on file, without the underlying clinical support behind it, is exposed even when the prescription itself was filled correctly.
Quantity Limits and Refill Timing
GLP-1 products are dispensed on a titration schedule that changes the dose, and sometimes the days' supply, over the course of therapy. PBM claims systems flag refills that arrive earlier than the prior fill's days' supply would allow, and a pattern of early refills across multiple patients draws the same scrutiny an inventory shortfall finding draws in a conventional audit. Auditors also compare the quantity dispensed against the plan's published quantity limit for that specific brand and dose, since weight-management-indicated products frequently carry tighter monthly limits than diabetes-indicated products at the same milligram strength. A pharmacy that adjusts a days' supply calculation to accommodate a dose titration, without a chart note explaining the change, risks having every affected claim treated as an unsupported early fill.
A prior authorization approval on file answers only part of the auditor's question. The chart still has to show why the patient qualified under the criteria the plan actually applied.
From Audit Finding to Recoupment and Termination
A GLP-1 audit that closes with unsupported findings does not usually stop at the recoupment demand. The same documentation gaps that support a recoupment finding, particularly a pattern of diagnosis mismatches or unsupported prior authorizations, are the pattern PBMs point to when a pharmacy's contract goes to a termination for cause review. Pharmacies that have already lived through the escalation from an audit finding to network termination know the sequence moves faster once a PBM treats the documentation gap as systemic rather than isolated to a handful of claims. An audit appeal filed before the recoupment demand hardens into a termination referral has meaningfully more room to work with than one filed after.
Why Early Legal Counsel Is Critical
It is critical that pharmacies promptly retain experienced healthcare defense counsel upon receiving a PBM audit notice that targets GLP-1 claims. Early legal intervention can protect the pharmacy's rights, ensure the documentation assembled for the response matches the coverage criteria the PBM actually applied, avoid inadvertent admissions about diagnosis or dosing decisions, and preserve the record for a later audit appeal. Delaying legal representation can significantly affect the outcome of the audit and expose the pharmacy to recoupment and network termination risk that a timely, well-documented response could have avoided.
How Health Law Alliance Can Help
Health Law Alliance defends pharmacies nationwide against PBM audits of brand GLP-1 claims, from the initial documentation request through the audit appeal and any related network termination proceeding. The firm has overseen 2,000+ audits across the PBM landscape, including the newest wave of GLP-1-specific reviews. If your pharmacy has received a GLP-1 audit notice, contact us for a free, confidential consultation.
